Pegylated-Proline-interferon alpha-2b not checked
AOP Orphan Pharmaceuticals AG · AOP2014
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Ropeginterferon alfa-2b 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.”In the company’s words, NCT06514807 on ClinicalTrials.gov
- Tested for
- Essential Thrombocythaemia
- Main trialPhase 3
- “The primary objective of this study is to assess the efficacy of ropeginterferon alfa-2b in patients with ET who need cytoreductive treatment but are intolerant or refractory to, and/or ineligible for cytoreductive treatments approved and available for the treatment of ET (i.e., HU, ANA, BUS, and PB, when they are available and approved for ET treatment). Ropeginterferon alfa-2b is currently the only interferon authorised as a cytoreductive treatment of a myeloproliferative neoplasm (MPN), and the long-term treatment data from its comprehensive clinical development program show its efficacy…”In the company’s words, NCT06514807 on ClinicalTrials.gov
- Other names
- AOP2014
Other drugs for Essential Thrombocythaemia
- BomedemstatMerck & Co. · Phase 3
- INCA033989Incyte Corporation · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- Givinostat HydrochlorideItalfarmaco · Phase 2
- STP938Step Pharma, SAS · Phase 2
- JBI-802Jubilant Therapeutics Inc. · Phase 1/2
Coming up1
- 15 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 15 Mar 2028 | A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients | |
| Phase 3Completed | 29 Apr 2021 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. | |
| Phase 2Authorised | not given | A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS: A RANDOMIZED PROSPECTIVE TRIAL (BosuPeg) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026